TS-066751 — In the rapidly evolving field of biotechnology and pharmaceuticals, there is a critical need for efficient delivery mechanisms to transport therapeutic agents directly into cells. Traditional methods face challenges with membrane impermeability and degradation of therapeutic compounds, limiting th…

TS-065809 — Therapeutic strategies for treating ocular neovascular disorders by targeting telomerase.

TS-064248 — The Notch signaling pathway is important in immune cell differentiation and maturation. As a result, it has been shown that Notch receptor signaling can promote or suppress adaptive immune responses depending on the particular ligands and receptors involved. A set of native protein-inspired biolog…

TS-062739 — Method to program pericytes for axon regeneration and spinal cord injury repair.

TS-062677 — Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum and prostate cancers. The Need Current cancer treatments mainly rely on chemotherapy, radiation, surgery and bon…

TS-062540 — General methods for purifying proteins that can be used in various applications such as targeted drug delivery, bioimaging, and hemolysis treatment.

TS-062097 — Novel polypeptides and polynucleotides targeting RyR2 to address dysregulated Ca2+ release.

TS-053103 — Uncontrolled hemolysis (i.e., destruction of red blood cells) is characterized by the increase of circulating toxic cell-free hemoglobin, heme and iron in the bloodstream. In vivo, the body’s natural supply of plasma scavenger proteins acts to neutralize these toxic species. However, these scavenger proteins such as haptoglobin, hemopexin and transferrin, which detoxify hemoglobin, heme and iron, respectively, are depleted in various clinical conditions such as hemorrhagic shock, burns, surgery, organ transplantation, sepsis and trauma. Dr. Andre Palmer’s lab at The Ohio State University has developed a novel therapeutic protein mixture, which can be used to treat plasma protein imbalances or depletion caused by the adverse events described above. The properties of this protein mixture are beneficial as they lend themselves to an inexpensive manufacturing process and potential improvements in clinical outcomes.

TS-050524 — Despite high vaccine coverage, whooping cough caused by Bordetella pertussis remains one of the most common vaccine-preventable diseases worldwide. Introduction of whole-cell pertussis (wP) vaccines in the 1940s and acellular pertussis (aP) vaccines in 1990s reduced mortality due to pertussis. Des…

TS-050433 — A gene therapy solution for Usher Syndrome Type 1F.